T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Sarepta Therapeutics
SRPT
$1.9B
| $593M | 0.08% |
3,902,227
+359,160
| +10% | +$43.6M |
|
252
Boston Scientific
BSX
$72.9B
| $591M | 0.08% |
13,748,652
+3,039,311
| +28% | +$117M |
|
253
Edison International
EIX
$26.7B
| $591M | 0.08% |
8,763,168
+4,625,141
| +112% | +$287M |
|
|
AVTR.PRA
254
DELISTED
Avantor, Inc. Series A Mandatory Convertible Preferred Stock
AVTR.PRA
| $588M | 0.08% |
+8,983,175
| New | +$558M |
|
255
Royal Caribbean
RCL
$81.7B
| $588M | 0.08% |
4,850,642
-440,510
| -8% | -$53.7M |
|
|
RHT
256
DELISTED
Red Hat Inc
RHT
| $587M | 0.08% |
3,124,298
-8,392,190
| -73% | -$1.55B |
|
257
FirstService
FSV
$6.22B
| $586M | 0.08% |
6,109,898
-913
| -0% | -$82.6K |
|
258
Union Pacific
UNP
$174B
| $582M | 0.08% |
3,441,974
-380,850
| -10% | -$65.3M |
|
259
Teledyne Technologies
TDY
$31.5B
| $580M | 0.08% |
2,116,375
-16,813
| -0.8% | -$4.19M |
|
260
Republic Services
RSG
$66B
| $580M | 0.08% |
6,689,048
-420,187
| -6% | -$35M |
|
261
Bristol-Myers Squibb
BMY
$130B
| $578M | 0.08% |
12,749,545
+3,816,247
| +43% | +$178M |
|
262
Enovis
ENOV
$1.37B
| $575M | 0.08% |
11,926,240
+3,217,431
| +37% | +$155M |
|
263
CSX Corp
CSX
$92.5B
| $570M | 0.08% |
22,099,785
+547,752
| +3% | +$14.1M |
|
|
SGEN
264
DELISTED
Seagen Inc. Common Stock
SGEN
| $568M | 0.08% |
8,203,502
+108,801
| +1% | +$7.62M |
|
265
Canadian Pacific Kansas City
CP
$81.2B
| $564M | 0.08% |
11,984,560
-388,750
| -3% | -$17.4M |
|
266
Northern Trust
NTRS
$34.7B
| $560M | 0.08% |
6,221,336
+390,783
| +7% | +$36M |
|
267
O'Reilly Automotive
ORLY
$74.4B
| $560M | 0.08% |
22,732,470
+27,300
| +0.1% | +$692K |
|
268
argenx
ARGX
$54.6B
| $539M | 0.08% |
3,806,592
+209,848
| +6% | +$26.6M |
|
|
THS
269
DELISTED
Treehouse Foods
THS
| $534M | 0.08% |
9,866,963
+20,144
| +0.2% | +$1.18M |
|
|
RP
270
DELISTED
RealPage, Inc.
RP
| $530M | 0.07% |
9,001,300
-52,112
| -0.6% | -$3.16M |
|
271
Rayonier
RYN
$6.38B
| $526M | 0.07% |
19,122,717
+183,910
| +1% | +$5.14M |
|
272
AstraZeneca
AZN
$246B
| $525M | 0.07% |
6,357,973
+747,218
| +13% | +$58.6M |
|
273
Progressive
PGR
$123B
| $523M | 0.07% |
6,540,925
-1,224,146
| -16% | -$94.7M |
|
274
SL Green Realty
SLG
$3.97B
| $516M | 0.07% |
6,638,701
+32,359
| +0.5% | +$2.73M |
|
|
FTCH
275
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $513M | 0.07% |
24,656,061
+7,886,096
| +47% | +$182M |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.